Premium Global Health Research
We explore health research from around the world and translate complex science into information people can understand, question, and evaluate.
Educational & research use only. Not medical advice — we do not sell or promote any compounds. Read the full disclaimer.
From the journal
JournalThe medical establishment has an accountability problem — and the public is paying attention. Credentials aren't evidence. Headlines aren't evidence. Clinical anecdotes aren't controlled studies. Allegations aren't established causation.
JournalTwo deaths involving products reportedly sold as retatrutide deserve careful investigation. What do clinical studies tell us about adverse effects, warning signs, and the limits of what can be concluded?
JournalEntering the peptide business in 2026 without understanding the surrounding infrastructure can be a costly education. BioMaxFit examines ten business realities — from supply-chain verification and credit-card processing to marketing footprints and medical-liability lines — that anyone should understand before deciding whether this industry makes sense at all.
JournalA preclinical five-receptor agonist nicknamed 'GLP-5' produced greater weight loss than retatrutide in a diet-induced obese rat model presented at ADA 2026. BioMaxFit examines what the animal data actually show, why the amylin axis is the new frontier, and why a rat readout is directionally interesting — not decisive.
JournalPremixed peptide products combine every supply-chain risk into one: unverifiable concentration, no traceability or independent testing, cold-chain degradation in transit, and serious criminal liability for the unlicensed person who mixed them.
JournalA no-frills reference: which peptides the FDA has approved, which it has not, and which are caught up in active lawsuits.
JournalA comprehensive two-section reference listing every known peptide and compound on the market — FDA-approved with dosing, and grey-market with risks and legal status — plus the compounds currently under active FDA enforcement and Eli Lilly lawsuit scrutiny.
JournalAn investigative deep dive into retatrutide — the triple-agonist compound from Eli Lilly that has not been approved, has not finished clinical trials, and is being sold by the thousands to consumers through a grey market now facing federal lawsuits, cease-and-desist campaigns, and criminal investigations.
JournalWhy supply-chain integrity matters more than price — and what every buyer should know about unverifiable sources.
JournalA measured look at molecular hydrogen water — the proposed mechanisms and where the evidence stands today.
JournalElectrolytes, timing, and the small signals your body sends when it needs more than a glass of water.
JournalWhy adaptation happens during recovery, not during the workout — and how to plan for it.
JournalSupplements work best on top of solid fundamentals — not as a replacement for them.
JournalWhy no habit returns more per unit of effort than protecting your sleep.
Original articles researched and written by our editorial team.
Content grounded in published science and cited sources.
BioMaxFit is an independent entity, operated separately from any product brand.
Education and lifestyle goods — never medical devices or treatments.
Join our reader list for new articles, wellness insights, and product updates — delivered occasionally, never spam.
Contact to Learn MoreMedical & Educational Disclaimer
BioMaxFit is a 100% educational and research-only journal. We do not sell, promote, or recommend any peptide, compound, or product. The content on this site is for educational and informational purposes only and is not medical advice. BioMaxFit is not your doctor and does not provide medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, changing, or stopping any wellness regimen, supplement, or protocol. Statements regarding compounds discussed on this site have not been evaluated by the Food and Drug Administration. Read the full disclaimer.